CSF1R and ovarian carcinoma: Investigations of CSF-1R antibodies in patients with advanced solid tumors include: 1) AMG 820 [123], emactuzumab, in monotherapy or plus paclitaxel [124], and LY3022855, plus durvalumab or tremelimumab [125], each displaying modest activity in ovarian cancer patient subsets.